This study aims to utilize the FAERS database to compare the risks of nervous system-related adverse events associated with different ROS1 inhibitors in NSCLC patients and explore their onset timing and potential risk factors influencing patient outcomes, thereby providing valuable reference information for clinical practice. Here, ROS1 is linked to non-small cell lung carcinoma.